Page 6 - Ipca Labs News Today

A slow offtake in the acute season resulted in weaker sales within the segment, dragging overall sales growth in the domestic pharma market in July.

The ace investor also expects significant buying by foreign and domestic institutional investors in the days ahead

On the domestic front, the RBI interest rate decision will be the key factor to watch out for, while globally, the participants will take cue from the US inflation numbers releasing on August 10.

Ipca Labs had informed the exchanges last week of receiving a go ahead from the Competition Commission of India for acquiring a majority stake in Unichem Labs.

​But we look at this as an opportunity to create fresh trades and a fall to 19,430 or something would be broadly called shallow, although from the high of 19,990 you may say okay it is like 3-4% or something but that is fair.

The article highlights the remarkable performance of stocks that crossed their 200-day Simple Moving Average (SMA) on July 27, 2023. Godfrey Phillips India and Granules India take the lead, alongside other prominent companies like Ipca Laboratories and United Breweries, showcasing positive market sentiment and growth potential.

HDFC mutual funds prominent reductions last month included Hindustan Aeronautics, Tata Motors and Indian Hotels among others. On the other hand, it lapped up shares of ICICI Bank and HPCL along with Ipca Labs and few others

Indian drugmakers outperformed multinational pharma players in the Indian Pharma Market in May, a trend that has been going on since the past 12 months.

Shares of Indian pharmaceutical company, Ipca Laboratories, fell by 3% after the US Food and Drug Administration (USFDA) issued a Form 483 report, citing 11 observations of its API manufacturing facility situated in Ratlam. Form 483 is issued when an inspector has found conditions that could violate FDA regulations. Ipca said it takes quality and compliance issues seriously and will submit a response in the prescribed time. Trendlyne data showed that the stocks day RSI (14) is at 57.8, while the...

Not just pharma companies, JM Financial also sees a bright future for diagnostics as well as hospital players in FY24